跳至主要内容
临床试验/NCT06904287
NCT06904287招募中3 期

Evaluating the Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines in the Emergency Department

Wake Forest University Health Sciences1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2025年12月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
100
试验地点
1
主要终点
Mean change in pain - baseline to 30 minutes

研究概览

简要总结

The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.

详细描述

The purpose of this prospective, randomized, double-blinded study is to compare the relative efficacy and safety of intravenous magnesium in conjunction with intravenous prochlorperazine in the treatment of migraines. Participants will be patients presenting to the Emergency Department with primary diagnosis of migraine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years or older
  • Able to provide informed consent
  • English speaking
  • Primary diagnosis of migraine. Patient with a previous diagnosis of migraine, who experience headaches with typical migraine features (e.g at least 2-3 of the following: recurrent, unilateral, pounding or throbbing in nature, associated with nausea), AND with a clinical exclusion of migraine mimics

排除标准

  • Pregnancy defined as a positive urine HCG
  • Allergy or sensitivity to study drug
  • Stated history of renal insufficiency
  • Documented history of myasthenia gravis
  • Consumption of study drug within 48 hours prior to enrollment
  • Previously enrolled in this trial during a different patient encounter

研究组 & 干预措施

Study Drug

Experimental

Prochlorperazine 10 mg followed by Magnesium 2 g

干预措施: Magnesium (Drug)

Control Arm

Active Comparator

Prochlorperazine 10 mg followed by placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Mean change in pain - baseline to 30 minutes

时间窗: Baseline to 30 minutes after initiation of infusion

Change in pain score 30 minutes after initiation of infusion. Pain score is measured on a 0-11 point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain.

次要结局

  • Mean change in pain - baseline to 45 minutes and baseline to 60 minutes(Baseline to 45 minutes and 60 minutes after initiation of infusion)
  • Number of adverse events(Infusion through hour 2)
  • Emergency Department length of stay(Hour 24)
  • Number of patients that require rescue medications(Infusion through hour 2)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验